Robert Mannino

Robert Mannino is the current Chief Technology Officer at Sanguina. Robert was previously an R&D Systems Engineering Intern at Immucor, Inc. from July 2017 to October 2017, where they facilitated crosstalk between biological assay development and hardware engineering teams and implemented software and mechanical design improvements in the development of a novel, automated red blood cell typing and antibody screening medical device and developed SOPs detailing the use of the device. Prior to that, they were a PHD Candidate at the Georgia Institute of Technology from August 2013 to May 2018, where they developed a point-of-care, smartphone image analysis diagnostic for anemia (affects 2 billion people worldwide). Robert conducted a clinical study to validate diagnostic accuracy, preliminary results are comparable to gold standard diagnostic blood sampling tools. Publication under review. Robert also developed mobile medical apps for multiple smartphone operating systems allowing patients to self-monitor anemia. Robert secured IRB approval to conduct a clinical study to evaluate diagnostic accuracy. In addition, they designed and fabricated a “Do it yourself” endothelialized microfluidic device capable of recapitulating various cardiovascular geometries for the study of hematologic diseases resulting in two first-authored publications.

Robert Mannino has a Ph.D. in Bioengineering and Biomedical Engineering from the Georgia Institute of Technology. Robert also has a Bachelor's Degree in Bioengineering and Biomedical Engineering from the Georgia Institute of Technology.

Robert Mannino reports to Erika A. Tyburski, CEO & Co-Founder. Robert Mannino works with Morgan Decker - Director of Marketing, Wilbur Lam - Chief Medical Officer & Co-Founder, and René González - CFO. A direct report to Robert Mannino is and Zack Moss - Mobile Developer.